Bioequivalence Study of Gabapentin 800 mg Tablets Under Fasting Conditions
Status:
Completed
Trial end date:
2002-12-01
Target enrollment:
Participant gender:
Summary
This study compared the relative bioavailability (rate and extent of absorption) of the test
Gabapentin tablets 800 mg by Ranbaxy Laboratories Limited to the reference Neurontin ® 800 mg
tablets of Parke Davis Pharmaceuticals Ltd., distributed by Parke Davis, division of
Warner-Lambert Co. in 28 healthy, adult subjects (21 males and 7 females) under fasting
conditions using randomized, two-way crossover design.